Detalhe da pesquisa
1.
Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
Clin Cancer Res
; 29(11): 2034-2042, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37014667
2.
Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Blood Adv
; 6(22): 5857-5865, 2022 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36150050